Q-Antiacne
Gel
A Multi-Target, Non-Antibiotic Topical Therapy for Mild-to-Moderate Acne Vulgaris.
Prepared for: Crassula Cosmeceutical Division
"Clinical precision for acne control. Antibiotic-free."
by Day 28
by Day 28
Progressive visible reduction
Clinical Study
1. Executive Summary
Addressing the Clinical Burden
of Acne Vulgaris
Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit with substantial clinical, psychosocial, and economic burden. Existing topical therapies—particularly antibiotics, benzoyl peroxide, and retinoids—are effective but limited by irritation, antimicrobial resistance, and poor long-term adherence.
Q-ANTIACNE Gel is a scientific-grade, non-antibiotic, non-steroidal topical formulation designed to address all four core pathogenic drivers of acne:
Rapid, Statistically & Clinically Meaningful Improvement
Clinical evaluation in 60 patients with mild-to-moderate acne vulgaris demonstrated rapid, statistically and clinically meaningful improvement within 14 days, with sustained outcomes at 28 days and excellent tolerability.
2. Pathophysiology of Acne Vulgaris
Scientific Basis
Acne vulgaris arises from a convergence of four mechanisms. Unlike monotherapy approaches, Q-ANTIACNE is engineered as a multi-pathway intervention, interrupting acne progression at multiple biological checkpoints simultaneously.
3. Formulation Rationale
Mechanism of Action
Mechanism →
Disrupt microbial membranes, inhibit biofilm formation, and suppress C. acnes without inducing antibiotic resistance.
Mechanism →
Downregulate NF-κB signaling, reduce cytokine-mediated erythema and edema.
Mechanism →
Normalize sebocyte activity, reduce follicular plugging, and improve barrier integrity.
Mechanism →
Promote fibroblast activity, extracellular matrix (ECM) regeneration, and post-inflammatory pigment control.
4. Role of QuanticSphere™ PQNS Technology
Advanced Delivery System
Q-ANTIACNE integrates phospholipid-based PQNS vesicles to enhance topical performance. PQNS provides delivery precision without systemic exposure, aligning with medical-grade dermatologic safety standards.
5. Clinical Study Design
Rigorous Clinical Evaluation
| Parameter | Detail |
|---|---|
| Study Type | Prospective, open-label, single-arm clinical evaluation |
| Population | 60 patients (15–35 years) with mild-to-moderate acne vulgaris |
| Treatment Regimen | Q-ANTIACNE Gel applied twice daily for 28 days |
| Assessment Timepoints | Day 0 (baseline), Day 14, Day 28 |
| Endpoints | Inflammatory lesion count, non-inflammatory lesion count, erythema, oiliness, PIH scores, safety & tolerability |
6. Associated Symptoms — Results
by Day 28
by Day 28
7. Safety & Tolerability
Excellent Safety Profile
This safety profile supports long-term use, including in sensitive and acne-prone skin populations.
8. Clinical Positioning
Q-ANTIACNE Gel
is positioned as:
Next-Generation
Acne Therapy
Q-ANTIACNE is a scientific-grade cosmeceutical for inflammatory, hormonal, and recurrent acne, combining multi-target action with advanced delivery technology (QuanticSphere™) to deliver clinically effective and well-tolerated acne control without antibiotics.
Contact the Medical TeamDownload the
Clinical Dossier
Enter your email address to access the full Q-ANTIACNE Gel technical and clinical PDF — free of charge.
🔒 Your data is protected under GDPR. We will never share your information with third parties.
You’re all set!
Thank you. Your download is ready. Click below to get the Q-ANTIACNE Gel clinical dossier.